Ubiquinol (Reduced COQ10) for Patients With Sepsis

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to determine if Ubiquinol (reduced form of COQ10) will attenuate mitochondrial injury and decrease inflammatory response in patients suffering from sepsis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Collaborators: Kaneka Medical America LLC; Kaneka Pharma America LLC
• Treatments: Ubiquinone

Criteria

Inclusion Criteria:

• Over 18 years old

• Suspected or confirmed infection

• Presence of 2 or more systemic inflammatory response syndrome (SIRS) criteria

• Admission to the ICU

Exclusion Criteria:

• Under 18 years old

• Current CoQ10 supplementation

• Unable to receive enteral medications

• Would need a nasogastric or orogastric tube solely for the purposes of the study

• Pregnancy, incarceration, mentally disability

• Patient confirmed Comfort measures only, Do not resuscitate (DNR) and/or Do not intubate. Patients with DNR but intubated and being provided full care are eligible